Key Highlights

  • 4D Molecular Therapeutics Chief Legal Officer Scott Bizily executed a sequence of option exercises and subsequent sales.
  • The transactions involved 584 shares at prices between $6.49 and $14.
  • The sales leave Bizily with a direct stake of 8,617 shares.
  • The transaction was not accompanied by new clinical, regulatory, or Capital allocation news.

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) Chief Legal Officer Scott Bizily executed a sequence of option exercises and subsequent sales involving 584 shares at prices between $6.49 and $14.

What Happened

The transactions left Bizily with a direct stake of 8,617 shares. This transaction represents a routine insider adjustment and was not accompanied by any new data from clinical trials, regulatory updates, or capital allocation news.

Market Reaction

The disclosed information does not include stock price or trading data for 4D Molecular Therapeutics tied specifically to this insider transaction.

Outlook

The disclosed information does not include specific forward guidance beyond this routine insider transaction.